Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Siglec-6 CAR-T cells (Xuzhou Medical University)
- Development stage
- Unknown
- Lead developer
- Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-Siglec-6 CAR-T cell therapy is an autologous chimeric antigen receptor (CAR) T-cell immunotherapy developed by Xuzhou Medical University for the treatment of relapsed and refractory acute myeloid leukemia (AML). The therapy involves genetically engineering a patient's T cells to express a CAR that targets Siglec-6 (sialic acid-binding immunoglobulin-like lectin 6), using a targeting domain derived from the human monoclonal antibody JML-1. Siglec-6 is highly expressed on AML blasts and leukemic stem cells but is absent on normal hematopoietic stem and progenitor cells (HSPCs), potentially reducing off-target myelotoxicity. The therapy is currently undergoing Phase 1/2 clinical evaluation to assess its safety and efficacy in patients with advanced AML.
- Other names
- anti-Siglec-6 CAR-T cell therapyanti-Siglec6 CAR-T cell therapyanti-Siglec 6 CAR-T cell therapySiglec-6 CAR-TSiglec6 CAR-TSiglec 6 CAR-T
02
Targets
SIGLEC6 (Siglec-6)
Beyond the preview
Go deeper on anti-Siglec-6 CAR-T cells (Xuzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Siglec-6 CAR-T cells (Xuzhou Medical University).